Our previous studies showed that the urokinase-type plasminogen activator receptor (uPAR) and the p16 tumor suppressor gene play a signi®cant role in glioma invasion. We expected that downregulation of uPAR and overexpression of p16 using a bicistronic vector might cause a additive and cooperative eect in the suppression of glioma invasion and growth. The bicistronic construct (Ad-uPAR/p16)-infected glioblastoma cell lines had signi®cantly lower levels of uPAR and higher levels of p16 than controls. Cell cycle analysis showed the bicistronic vector caused G0/G1 arrest of the cell cycle. In vitro glioblastoma cell growth and invasiveness were inhibited in Ad-uPAR/p16-infected cells compared with controls. Ad-uPAR/p16 suppressed the tumor growth of glioblastoma cell lines in an ex vivo intracerebral tumor model and an in vivo subcutaneous tumor model. Our results support the therapeutic potential of simultaneously targeting uPAR and p16 in the treatment of gliomas. Oncogene (2002) 21, 87 ± 95.
Introduction
Malignant gliomas grow extensively and in®ltrate the surrounding normal brain, and their diuse invasion is one of the most important barriers to successful therapy. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) have key roles in the event of tumor cell invasion. uPA is a serine protease that catalyzes the conversion of inactive plasminogen into plasmin, which degrades extracellular matrix proteins and activates metalloproteases and growth factors (Mignatti and Rifkin, 1993; Murphy et al., 1992) . uPA binds its cell-surface receptor (uPAR), thereby increasing proteolytic activity at the cell surface (Vassalli et al., 1985) . The binding of uPA to uPAR not only increases proteolytic activity of uPA but also favors a focal and directional proteolysis of extracellular matrix molecules (Pollanen et al., 1991) . In our earlier studies of human gliomas, uPAR expression was greater in the high-grade tumors than in the low-grade gliomas (Yamamoto et al., 1994a) . The binding between uPA and uPAR is thought to play a major role in the invasion of glioblastoma cells into normal brain by virtue of concentrating the proteolytic activity at the leading edge of the tumor (Yamamoto et al., 1994a,b) . The expression of uPAR by human glioblastoma cells might signi®cantly contribute to their invasive capacity (Mohanam et al., 1993) . Stable transfectants of the human glioblastoma cell line SNB19 with antisense uPAR-expressing plasmid DNA have been shown to alter the invasiveness of these cells both in vitro and in vivo . Transfecting the low-grade neuroglioma cell line H4, which normally expresses low levels of uPAR, with full-length uPAR cDNA increased uPAR expression; the transfected cells showed high invasiveness compared with the parental cells (Mohanam et al., 1998) . Recently we reported that downregulating the uPAR level by an antisense strategy using an adenovirus construct (AduPAR) inhibited glioma invasion in vitro and inhibited tumor formation and growth in vivo (Mohan et al., 1999) . It has been reported that downregulation of uPAR expression with an antisense strategy induced a protracted period of tumor dormancy causing cells to be arrested at the G0/G1 phase in vivo, but not aecting their in vitro growth (Yu et al., 1997; Aguirre et al., 1999) .
The p16 gene localized to the 9q21 chromosomal region encodes a M r 16 000 protein (Kamb et al., 1994; Serrano et al., 1996) . The p16 is a major tumor suppressor gene. Inactivation of p16 is critical for the formation of many human cancers (Fueyo et al., 1998) . In gliomas, p16 is inactivated more than 50% of tumors either by homozygous deletion (Jen et al., 1994) , mutation (Kyritsis et al., 1996) , or methylation (Costello et al., 1996; Fueyo et al., 1996a) . The p16 protein acts as a cyclin-dependent kinase inhibitor. This protein inhibits the binding of the cdk4 protein to cyclin D1, thus preventing phosphorylation of the Rb protein and arresting the cell cycle in the G1 phase. Restoration of p16 expression in glioma cells inhibits cell growth by blocking cell-cycle progression in the G1 phase (Arap et al., 1995) and modi®es several properties of the transformed cells (Fueyo et al., 1996b) . Moreover, we have reported that overexpression of the p16 gene considerably reduces glioma cells' ability to invade normal brain . p16 may also induce apoptotic death in transduced malignant cells (Schreiber et al., 1999; Gotoh et al., 1997; Naruse et al., 1998; Frizelle et al., 1998) . Thus, overexpression of p16 downmodulates the expression of the Rb protein, thereby minimizing the anti-apoptotic eect of Rb and sensitizing cancer cells to apoptotic stimuli (Sandig et al., 1997; Wang et al., 1997; Kyritsis, 1997) .
In the present study, we constructed a bicistronic replication-de®cient adenovirus vector containing uPAR antisense and p16 sense expression cassettes (Ad-uPAR/p16) with the intent of eectively delivering an antisense uPAR and sense p16 gene that would downregulate uPAR levels and overexpression of p16 levels in human gliomas. We examined the biological activity of the Ad-uPAR/p16 construct in human gliomas in both in vitro and in vivo models.
Results
Ad-uPAR/p16 overexpressed p16 and decreased uPAR protein level Figure 1a shows that the uPAR protein band (M r 60 000) decreased in a dose-dependent fashion as the MOI increased. Densitometric quanti®cation of the uPAR protein band on the Western blot showed a signi®cant (P50.001) decrease in the cells infected with Ad-uPAR/p16 at an MOI of 25. This decrease reached more than 90% in cells infected with Ad-uPAR/p16 at an MOI of 100 (with the percentage decrease determined relative to those in Ad-CMV (cytomegalovirus) vector-infected control cells).
Conversely, the p16 protein band (M r 16 000) increased in a dose-dependent fashion as the MOI increased. Densitometric quanti®cation of the p16 protein band on the Western blot showed a signi®cant increase (P50.001) in the cells infected at 100 MOI as opposed to 25 MOI. Figure 1b shows that the decrease in the uPAR protein level was related to time; that is, the SNB19 cells infected with Ad-uPAR/p16 at 100 MOI showed a 90% decrease in the uPAR level by day 5. On the other hand, p16 protein levels appeared on day 1 after infection of Ad-uPAR/p16 at 100 MOI and stayed at the same level until day 7, but these levels were reduced by 25% at day 10 and by 75% at day 14. The b-actin level did not change under any of the above conditions indicating that similar amount of protein had been loaded in each lane.
Ad-uPAR/p16 inhibited the cell growth of human glioma cells Figure 2a shows that there was a signi®cant decrease in the growth of cells infected at 25 MOI; and this eect was dose-dependent, with only 7 ± 10% cells tested at 100 MOI surviving at day 8. For comparison we also examined the eect of infection with Ad-CMV (100 MOI), Ad-uPAR, Ad-p16 and Ad-uPAR/p16 on the survival of SNB19 cells at various times (Figure 2b ). Although there was no reduction in the survival of cells infected with Ad-CMV and Ad-uPAR, there was a signi®cant (P50.001) decrease in the survival of cells infected with Ad-p16 (45 ± 50%) and Ad-uPAR/p16 (20 ± 25%) at 25 MOI. The eect was very high for the Ad-uPAR/p16 construct compared with Ad-p16.
Ad-uPAR/p16 decreased Rb/E2F1 cell cycle regulating proteins Figure 3a shows that the Rb protein and E2F1 protein levels decreased more than 90% in response to 25 MOI Ad-uPAR/p16 compared with mock and Ad-CMV controls, but there was not much more dierence in the levels at higher MOI doses of the Ad-uPAR/p16 construct. Densitometric quantitation of Rb and E2F1 protein bands on Western blots showed a signi®cant decrease (P50.001) when the cells were infected with Ad-uPAR/p16 at 25, 50 and 100 MOI compared with mock and Ad-CMV controls. However, there was no dierence in the Rb and E2F1 protein levels starting 1 day after infection of the SNB19 ells with Ad-uPAR/p16 at 100 MOI compared after 5 days but the eect was highly signi®cant compared with mock and Ad-CMV controls (Figure 3b ). Quantitation of Rb and E2F1, protein bands on Western blots on day 1 showed a signi®cant decrease (P50.001) when the cells were infected with Ad-uPAR/p16 at 100 MOI compared with mock and Ad-CMV controls. The bactin level did not change under any of the above conditions, indicating that similar amounts of protein had been loaded in each lane.
Ad-uPAR/p16 caused G1 arrest in SNB19 cells
To con®rm that Ad-uPAR/p16 altered the cell cycle of SNB19 glioma cells, we performed¯owcytometry studies. On the fourth day after infection, 72.9% of the Ad-p16-treated (at 50 MOI) and 73.3% of the Ad-uPAR/p16-treated (at 50 MOI) SNB19 cells were accumulated in G0/G1 phase. On the other hand, 47.0% of the Ad-uPAR-treated (at 50 MOI) and 46.5% of the Ad-CMV-treated (at 100 MOI) SNB19 cells were accumulated in G0/G1 phase. This accumulation of cells in G0/G1 phase correlated with an under-representation of the S phase cell population in the cells treated with Ad-p16 and Ad-uPAR/p16 in comparison with the cells infected with Ad-uPAR and Ad-CMV (12.5% of Ad-p16-and 10.2% of Ad-uPAR/ p16-treated cells versus 37.3% of Ad-uPAR-and 43.5% of Ad-CMV-treated cells) (Figure 4 ).
Ad-uPAR/p16 inhibited the invasiveness of SNB19 cells
The eect of Ad-uPAR/p16 infection on the invasiveness of SNB19 was studied using a Matrigel model that compared the invasion of infected cells through matrixcoated ®lters with that of mock and Ad-CMV controls. SNB19 cells were seeded at a density of 1610 6 cells/ml in the upper chamber and quantitated by 3-(4, 5-dimethylthiazol-2-ml); 2, 5-diphenyltetrazdium bromide (MTT) assay (Mohanam et al., 1993) , the results showed that 45 ± 43% of parental cells and 46 ± 42% of Ad-CMV-transfected cells had invaded to the lower side of the membrane at 48 h. In the SNB19 cells transfected with Ad-uPAR and Ad-p16 at 5, 25 and 50 MOI, the percentages of Ad-uPAR-transfected cells that invaded Matrigel were 40, 36 and 26% and the percentages of Ad-p16-transfected cells that invaded Matrigel were 38, 30 and 20%, respectively. In contrast, only 22, 14 and 5% of Ad-uPAR/p16-transfected cells invaded to the lower part of the membrane at 5, 25 and 50 MOI; the decrease was statistically signi®cant (P50.0001). At each dose level (5, 25 and 50 MOI), invasiveness was signi®cantly decreased in Ad-uPAR/p16 transfected cells compared with parental and Ad-CMV; Ad-uPAR and Ad-p16-transfected cells. Signi®cant inhibition was noticed at 5, 25 and 50 MOI of Ad-uPAR/p16 compared with the ®ndings in parental and Ad-CMV-transfected cells. Only at 50 MOI of Ad-p16 and Ad-uPAR was signi®cantly decreased invasiveness than that of parental and Ad-CMV-transfected cells ( Figure 5 ). The eect of Ad-uPAR/p16 infection on the invasiveness of SNB19 was also studied using spheroid models. In these experiments, the invasion of Ad-uPAR/p16-transfected cells into fetal rat brain aggregates was compared with that of cells infected with mock, Ad-CMV, Ad-uPAR, Ad-p16 and AduPAR/p16. The invasion of glioma spheroids infected with Ad-uPAR, Ad-p16 or Ad-uPAR/p16 was markedly dierent from that of glioma spheroids infected with Ad-CMV and for parental/mock cells during co-cultures with fetal rat brain ( Figure 6a ). Glioma spheroids infected with Ad-CMV or parental cells (mock) progressively invaded by approximately 90% at 72 h. However, glioma spheroids infected with Ad-uPAR at 5, 25 and 50 MOI in co-cultures with fetal rat brain aggregates progressively invaded by 90, 70 and 50%, respectively, by 72 h. Glioma spheroids infected with Ad-p16 at 5, 25 and 50 MOI progressively invaded by 85, 65 and 40%, respectively, by 72 h. However, glioma spheroids infected with Ad-uPAR/p16 at 5, 25 and 50 MOI progressively invaded by only 35, 22 and 5%, respectively, by 72 h. These results show that the bicistronic construct containing both antisense uPAR and sense p16 inhibited invasion by almost 70% at 5 MOI compared with the single constructs at the same MOI of antisense uPAR (10%) and sense p16 (15%). Further, these results show that higher doses (100 MOI) of Ad-p16 and Ad-uPAR inhibited almost 90% of invasion, as we reported previously Mohan et al., 1999) . However, the same or much stronger inhibition was obtained in response to about 20 ± 30 MOI of Ad-uPAR/p16 compared to 100 MOI of Ad-uPAR or Ad-p16 (Figure 6a ). Figure 4 Cell cycle analysis. SNB19 glioma cells were infected with either Ad-uPAR, Ad-p16, Ad-uPAR/p16 (50 MOI) or Ad-CMV (100 MOI). Cells were ®xed and stained with propidium iodide for¯ow cytometric analysis of the DNA content 4 days after infection as described in Materials and methods Ad-uPAR/p16 inhibited tumor formation and caused tumor regression in mice
We investigated the eect of Ad-uPAR/p16 infection on the growth of two glioblastoma cell lines in nude mice. An SNB19 variant that expresses b-galactosidase (facilitating the detection and measurement of tumor growth) was infected with Ad-uPAR/p16, Ad-CMV (100 MOI) or nothing (mock) and then injected intracerebrally into nude mice. All six of the mice in each group injected with noninfected cells and Ad-CMV-infected cells developed tumors; none of those animals injected with Ad-uPAR/p16-infected cells developed tumors over a 4 ± 5-week follow-up period (Figure 6b ). In a separate experiment, 4 ± 5-mm subcutaneous tumors were developed in nude mice by inoculation with U87MG cells. The tumors were injected every second day with phosphate buered saline (PBS; mock), Ad-CMV or Ad-uPAR/p16 (5610 8 plaque forming units (PFUs)) for a total of ®ve doses. All 10 Ad-uPAR/p16-injected mice showed tumor dormancy until 21 days, at which time Figure 6 (a) Tumor cell spheroid invasion into fetal rat brain aggregates. Confocal laser scanning images of SNB19 glioma spheroids infected with mock, Ad-CMV (100 MOI), Ad-uPAR, Ad-p16 and Ad-uPAR/p16 (5, 25, and 50 MOI) and rat brain aggregate co-cultures at dierent times. The images represented are the rat brain aggregates (green¯uorescence) and either mock-, Ad-CMV-, Ad-uPAR-, Ad-p16-or Ad-uPAR/p16-infected tumor spheroids (red¯uorescence). Inhibition of intracerebral tumor formation in nude mice and inhibition of subcutaneous tumor growth in nude mice. (b) SNB19 b-gal glioblastoma cell lines were infected with Ad-uPAR/p16, Ad-CMV (100 MOI) or nothing (mock) for 5 days, trypsinized, counted, and then inoculated intracerebrally (1610 6 cells in 10 ml of phosphate-buered saline (PBS) into nude mice (six mice each group). The animals were examined for tumor formation during a 4 week period, and the results were estimated using b-gal stain. (c) Nude mice were subcutaneously inoculated with U87MG (5610 6 cells in 100 ml of PBS). After 8 days, when the tumor diameter was between 4 and 5 mm, they were injected intratumorally with PBS (mock), Ad-CMV or Ad-uPAR/p16 (5610 8 PFUs) in a 100 ml volume. Injections were repeated a total of ®ve times, every other day, and the tumor size was measured using a caliper as described in Materials and methods. Tumor volumes are shown as mean+s. (Figure 6c ) was seen relative to the mock-and Ad-CMV-injected tumors.
Ad-uPAR/p16 induced apoptosis in SNB19 cells
To ascertain whether apoptosis was caused in treated SNB19 cells, we performed¯ow cytometric studies using terminal deoxynucleotidyl transferase end-labeling. Cell death of Ad-uPAR-, Ad-p16-, and Ad-uPAR/p16-treated (100 MOI) cell was compared with that of Ad-CMV-treated (100 MOI) and untreated (mock) cells. On the sixth day after infection, only 1.25% of the untreated and 1.70% of the Ad-CMV-treated SNB19 cells were apoptotic. Conversely, 4.45% of the Ad-uPAR-treated and 5.62% of the AD-P16-treated SNB19 cells were apoptotic. Moreover, 15.2% of the Ad-uPAR/p16-treated SNB19 cells were apoptotic (Figure 7 ).
Discussion
Malignant gliomas are the most common primary brain tumors in adults and children and are refractory to conventional forms of therapy (Walker et al., 1980) . They grow extensively and in®ltrate the surrounding normal brain, and their diuse invasion is one of the most important barriers to successful therapy. Controlling these tumors' invasion and growth simultaneously is an approach that must be investigated for its therapeutic potential. The present study involved consecutively targeting the uPA-uPAR system and the p16 tumor suppressor gene, which are critical for glioma invasion and growth, by using a bicistronic adenovirus vector containing uPAR antisense and p16 sense sequences.
Substantial evidence proves the involvement of the proteolytic cascade triggered by the uPA-uPAR system in the process of invasion (Ellis et al., 1992; Dear and Medcalf, 1998; Andreasen et al., 1997) . We previously observed that downregulation of uPAR decreased the invasiveness of glioma in vitro and in vivo Mohan et al., 1999) . The binding of uPA and uPAR not only increases proteolytic activity, but also favors a focal and directional proteolysis of extracellular matrix molecules (Pollanen et al., 1991) . The binding between uPA and uPAR is thought to play a major role in the invasion of glioblastoma cells into normal brain by virtue of concentrating the proteolytic activity at the leading edge of the tumor (Yamamoto et al., 1994a,b; Gladson et al., 1995) . From these reports, which implicate the uPA-uPAR system in invasion, it is logical to expect that downregulation of uPAR levels should result in an inhibition of invasion.
On the other hand, our data have also demonstrated a link between increased expression of the p16 gene and signi®cantly reduced invasiveness of glioma cells . In that report, the activity of matrix metalloprotease-2 (MMP-2) by gelatin substrate zymography was reduced after the transfer of p16. We also reported that antisense uPAR stable transfectants showed decreased levels of MMP2 compared to parental and vector controls. Several studies have implicated the expression of MMP-2 with the invasive process in vitro and in vivo Chintala et al., 1996) .
In the present study, a bicistronic replicationde®cient recombinant adenovirus vector containing uPAR antisense and p16 sense sequences was used to eectively downregulate uPAR levels and upregulate p16 levels in human glioma cells (Figure 1 ) and demonstrated a synergistic eect inhibition of these cells' invasiveness in Matrigel and spheroid models compared with the single expression vectors Ad-uPAR and Ad-p16 (Figures 5 and 6a) .
The p16 protein acts as a cyclin-dependent kinase inhibitor, inhibiting the binding of the cdk4 protein to cyclin D1 and thus preventing phosphorylation of the Rb protein and arresting the cell cycle in the G1 phase. Restoration of p16 expression in glioma cells inhibits cell growth by blocking cell-cycle progression in the G1 phase (Arap et al., 1995) . Other studies have suggested that downregulation of uPAR expression by using an antisense strategy did not aect glioma cell growth in vitro (Yu et al., 1997; Aguirre et al., 1999) . In the present study, Ad-uPAR/p16 downregulated the Rb/ E2F1 cell cycle regulators of SNB19 cells (Figure 3) . Cell cycle analysis showed Ad-uPAR/p16-and Ad-p16-infected cells to be in complete G0/G1 arrest, but AduPAR-and Ad-CMV-infected cells were not ( Figure  4 ). An in vitro cell growth assay showed that although there was no reduction in the survival of cells infected with Ad-CMV and Ad-uPAR, there was a signi®cant decrease in the survival of cells infected with Ad-p16 and Ad-uPAR/p16 at 25 MOI. The eect was very strong for the Ad-uPAR/p16 construct (Figure 2) . p16 may also induce apoptotic death in transduced malignant cells (Gotoh et al., 1997; Naruse et al., 1998; Frizelle et al., 1998) . Overexpression of p16 downmodulates the expression of the Rb protein, thereby minimizing the anti-apoptotic eect of Rb and sensitiz- Figure 7 Apoptosis assay. SNB19 glioma cells were infected with either Ad-uPAR, Ad-p16, Ad-uPAR/p16, Ad-CMV (100 MOI) or nothing (mock). Cells were ®xed and stained with TdT end-labeling and propidium iodide for¯ow cytometric analysis of the DNA content 6 days after infection as described in Materials and methods
Suppression of glioma invasion and growth by Ad-uPAR-p16
Y Adachi et al ing cancer cells to apoptotic stimuli (Sandig et al., 1997; Wang et al., 1997; Kyritsis, 1997) . In the present study, infection with Ad-uPAR/p16 caused a complete reduction of Rb proteins ( Figure 3 ) and induced apoptosis (Figure 7) . Interestingly, infection with Ad-uPAR/p16 induced more apoptotic cells than infection with Adp16. Infection with the Ad-uPAR single expression vector also showed some apoptotic eect on infected cells. These data suggest that both overexpression of p16 and downregulation of uPAR can induce apoptosis and that the bicistronic vector can cause an additive or synergistic apoptotic eect in infected cells.
Recently we reported that downregulating the uPAR level by means of an antisense strategy using an adenovirus construct (Ad-uPAR) inhibited glioma cell tumor formation and growth in vivo (Mohan et al., 1999) . Other papers have suggested that downregulation of uPAR expression using an antisense strategy induced a protracted period of tumor dormancy by arresting the cell cycle at the G0/G1 phase in vivo (Yu et al., 1997; Aguirre et al., 1999) . Adenovirus-mediated transduction of wild-type p16 into malignant cells has inhibited their tumorgenicity ex vivo and in vivo (Frizelle et al., 1998; Sandig et al., 1997) . It has been reported that the restoration of p16 protein inhibits avb3 integrinmediated cell spreading on vitronectin by blocking PKC-dependent localization of avb3 to focal contacts (Fahraeus and Lane, 1999) . The avb3 integrin receptor is closely associated with tumor growth and spread, both as a marker for invasive cancer cells such as malignant melanomas and grade III and IV glioblastomas and through its essential role in neovascularization (Brooks et al., 1994; Gladson and Cheresh, 1991) . Of further note the production of avb3 and uPAR is associated with invasive stages of other cancers, including aggressive glioblastomas (Yamamoto et al., 1994b; Dear and Medcalf, 1998; Fahraeus and Lane, 1999) . Most of these tumor types display an inverse correlation with the production of functional p16 tumor suppressor gene (Ichimura et al., 1996; Reed et al., 1995) in that the greater the invasive behavior, the lower the production of the p16 tumor suppressor gene. Studies have suggested that uPAR serves as a cell-surface receptor for the ECM protein vitronectin (Wei et al., 1994) and that uPAR mRNA expression is co-regulated with the expression of avb3 mRNA (Nip et al., 1995) . The induction of cell adhesion to vitronectin and the inhibition of cell adhesion to ®bronectin have been shown to depend in turn on the levels of uPAR on the cell surface (Wei et al., 1996) . A recent study showed that restoration of wildtype p16 downregulated vascular endothelial growth factor expression and inhibited angiogenesis in human gliomas (Harada et al., 1999) . From these reports, we expected a bicistronic vector containing uPAR antisense and p16 sense sequences might have a synergistic antitumor eect ex vivo and in vivo. In the present study, SNB19 b-gal cells infected with Ad-uPAR/p16 caused no tumors when injected into the brains of nude mice (Figure 6b) . Similarly, U87MG cells inoculated into nude mice subcutaneously and treated with intratumoral injections of Ad-uPAR/p16 showed tumor dormancy until 21 days, at which time approximately 90% inhibition of tumor growth relative to the mock-and Ad-CMV-injected tumors was evident (Figure 6c ). Taken together, our present data strongly support the therapeutic value of downregulating uPAR and overexpressing of p16 using an adenovirus bicistronic construct.
Materials and methods

Recombinant adenoviruses
We previously generated and reported the recombinant adenoviruses Ad-p16 and Ad-uPAR. Ad-p16 contains the CMV promoter, wild-type p16 complementary DNA and SV40 polyadenylation signal in a mini-expression cassette inserted into the E1-deleted region (Frizelle et al., 1998; Sandig et al., 1997; Wang et al., 1997; Kyritsis et al., 1996; Graham and Prevec, 1991) Ad-uPAR contains the CMV promoter, a truncated 300-bp antisense message complementary to the 5' end of the uPAR gene and bovine growth hormone polyadenylation signal in a miniexpression cassette inserted into the E1-deleted region (Mohan et al., 1999) . To construct Ad-uPAR/p16, the 2-kbp p16 miniexpression cassette was extracted by digestion with SalI and then ligated with pAd-uPAR-AS, which contains the uPAR antisense expression minicassette in the EcoRV site of the adenoshuttle vector pAd E1sp1A (Mohan et al., 1999) downstream of the uPAR antisense expression minicassette in the opposite orientation. This plasmid construct was cotransfected with PJM17 into human embryonic kidney 293 cells to isolate recombinant adenoviruses (Mohan et al., 1999) . The control virus Ad-EV was generated using pAd E1sp1A and PJM17.
Cell lines and infection conditions
The established human glioma cell line SNB19 (kindly provided by Dr Richard Morrison, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA), SNB19 b-galactosidase stable transfectant (SNB b-gal) (Go et al., 1996) and U87MG (The American Type culture Collection, Manassas, VA, USA) were used in the current study. The cells were grown in Dulbecco's modi®ed Eagles medium (DMEM)/F12 medium (1:1, v/v) supplemented with 10% fetal calf serum (FCS) in a humidi®ed atmosphere containing 5% CO 2 at 378C. Viral stocks were suitably diluted in serumfree medium to obtain the desire MOI or PFU and added to cell monolayers or tumor cell spheroids and incubated at 378C for 1 h. The necessary amount of culture medium with 10% FCS was then added, and the cells were incubated for the desired time periods.
Immunoblot analysis
For immunoblotting of p16, Rb and E2F1, total cell lysates were prepared by incubating the cells in RIPA buer (150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 20 mM EDTA, 50 mM Tris, pH 7.4 aprotinin and phenylmethylsulfonyl¯uoride). For immunoblotting of uPAR, total cell lysates were prepared in extraction buer containing Tris (0.1 M, pH 7.5), Triton X-114 (1.0%), EDTA (10 mM), aprotinin and phenylmethylsulfonyl¯uoride, and then the extracts were incubated at 378C for 10 min and centrifuged to separate the lower (detergent) phase, which contains mostly hydrophobic membrane proteins, including the glycosylphos-phatidylinositol-anchored uPAR. Twenty micrograms of protein from each sample was subjected to either 15% (p16), 10% (uPAR, E2F1) or 7.5% (Rb) SDS-Tris-Glycine gel electrophoresis and transferred to a nitrocellulose membrane (Schleicher and Schuell Inc., Keene, NH, USA). The membranes were probed with either rabbit anti-human p16 polyclonal antibody (C-20; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), rabbit anti-human uPAR polyclonal antibody (#399R; American Diagnostics Inc., Greenwich, CT, USA), rabbit anti-human Rb polyclonal antibody (C-15; Santa Cruz Biotechnology) or mouse antihuman E2F1 monoclonal antibody (#14971A; Pharmingen, San Diego, CA, USA). Mouse anti-human b-actin monoclonal antibody (Amersham Corp., Arlington Heights, IL, USA) was used as a loading control. Secondary antibodies (anti-rabbit-horseradish peroxidase or anti-mouse-horseradish peroxidase) were used as required and developed according to an enhanced chemiluminescence protocol (Amersham).
Measurement of tumor cell growth
SNB19 cells were seeded into 6-well plates at a density of 5.0610 4 cells/well. At speci®ed times after adenovirus infection, medium was removed from the wells, and cells were rinsed with PBS and trypsinized (0.25%), using scraping to recover all the cells. Cells were immediately added to 5 ml of growth medium containing 10% serum, pelleted by centrifugation, and then resuspended in 1 ml of PBS. Growth measurements for a speci®c day were obtained by counting triplicate wells of cells.
Cell cycle analysis
To measure DNA content, 10 6 cells either infected with adenovirus or treated with medium only (mock infected) were trypsinized 4 days after infection, ®xed 1% (w/v) paraformaldehyde in PBS and 70% cold ethanol, and incubated with propidium iodide (50 mg/ml) and ribonuclease (20 mg/ml) for 30 min at room temperature in the dark. The cells were analysed on a FACScan¯ow cytometer using CellQuest software (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). Gates were set using forward and side scatter parameters to determine the percentages of cells in G0/G1 phase and in S phase.
Matrigel invasion assay
The invasiveness of SNB19 human glioblastoma cells in vitro was assessed by measuring the numbers that passed through a Matrigel-coated plate (Corraborative Research Inc., Boston, MA, USA) with transwell inserts (Coster, Cambridge, MA, USA) according to a previously described procedure (Mohanam et al., 1993; Mohan et al., 1999; Chintala et al., 1997) . Brie¯y, transwell membranes with 12-mm pores were coated with a ®nal concentration of 0.78 mg/ ml Matrigel in cold serum-free DMEM. Cells were trypsinized, and 200 ml of cell suspension (1610 6 cells/ml) from each treatment was added into triplicate wells. After 48 h of incubation, the number of cells that passed through the ®lter into the lower wells was quanti®ed, and the values were expressed as a percentage of the total number of cells in the upper and lower wells (Mohanam et al., 1993) .
Spheroid invasion assay
Glioma spheroids of SNB19 cells were cultured in 100-mm tissue culture plates (Corning, Corning, NY, USA) precoated with 0.75% agar prepared in DMEM. Brie¯y, 2610 6 cells were suspended in DMEM, seeded onto agar-coated plates and cultured until spheroid aggregates were formed. Spheroids approximately 150 mm in diameter (4610 4 cells/spheroid) were selected and infected with adenovirus vectors (Mohan et al., 1999) . Three days after infection a glioma spheroid was placed in co-culture with a fetal rat brain aggregate 100 ± 200 mm in diameter. Invasion of the tumor spheroids into the fetal rat brain aggregates was analysed by confocal laser scanning microscopy (Zeiss LSM210, Thronwood, NY, USA) as described previously (Mohan et al., 1999; Chintala et al., 1997) .
Animal experiments
For the tumor regression experiments, U87MG cells (5610 6 cells) were s.c. injected into nude mice. After 8 days, when tumors had reached 4 ± 5 mm in diameter the mice were injected with PBS (mock) or Ad-CMV or Ad-uPAR/p16 (5610 8 PFUs) intratumorally every other day for a total of ®ve injections. Tumor size was measured every second day, and tumor volume was calculated from the formula 1/6p (R max )6(R min ) 2 , where R max and R min are the maximum and minimum tumor radii, respectively. For the intracerebral tumor model, SNB19 b-gal cells were infected in culture with PBS (mock) or Ad-CMV or Ad-uPAR/p16 (100 MOI) for 5 days, trypsinized, counted, and intracerebrally inoculated into nude mice. Six mice were killed 4 weeks after tumor inoculation from each group by cardiac perfusion with paraformaldehyde, and their brain was removed and frozen sections were prepared and stained for b-gal (Go et al., 1996) . The 12 ± 15 sections were blindly reviewed and scored semiquantitatively for the size of the tumor in each case. The average cross sectional diameter measured in sections of each tumor was used to calculate tumor size and compared between controls and treated groups. The variation between the sections in each group was less than 10%.
Apoptosis assay
Apoptotic cells were detected using TdT end-labeling and ow cytometry (APO-BRDU; Phoenix Flow Systems, San Diego, CA, USA). Brie¯y, 10 6 cells either infected with adenovirus or treated with medium only (mock infected) were trypsinized 6 days after infection and were harvested, washed in PBS, and ®xed in 1.0% paraformaldehyde and ice-cold 70% ethanol. The ®xed cells were then washed twice and the cell pellets incubated for 60 min at 378C in a labeling reaction mixture containing TdT reaction buer, Br-dUTP, dH 2 O and TdT. The reaction was terminated by adding the rinse buer. Incorporated Br-dUTP was detected after the addition of uorescein-labeled anti-bromodeoxyuridine antibody and incubation for 30 min at room temperature in the dark. To quantitate the total amount of DNA in the cells, a propidium iodide/RNase A solution was added and the tubes were incubated in the dark for an additional 30 min. The cells were analysed on the FACScan¯ow cytometer using CellQuest software. Gates were established on intact cells and analysed for DNA fragmentation and DNA amount to determine the percentage of apoptotic cells.
